Scinai Immunotherapeutics Ltd.
SCNI | NASDAQ
$1.91
+$0.22 (+13.02%)
At close: Sep 22, 2026, 4:00 PM ET
$1.73
-$0.18 (-9.42%)
After-hours:
Sep 22, 2026, 7:59 PM ET
Company Profile
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Key Executives
| Name | Position |
|---|---|
| Amir Reichman | Chief Executive Officer & Director |
| Elad Mark | Chief Operating Officer |
| Uri Ben-Or | Chief Financial Officer |
| Eran Kuratz | Head of Supply Chain & Business Process Administration |
| Gal Ron | Head of HR |
| Merav Kamensky | Head of Quality Control & GMP Analytics |
| Naama Adi Hen | Head of Quality Asurance |
| Tehila Sonnenfeld | Head of Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2026 | EFFECT | Filing |
| Aug 27, 2026 | POS AM | Filing |
| Aug 26, 2026 | 6-K | Filing |
| Aug 19, 2026 | 6-K | Filing |
| Jul 09, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 01, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 18, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
| Jun 17, 2026 | 6-K | Filing |
| Jun 15, 2026 | 6-K | Filing |
Scinai Immunotherapeutics Ltd.
| Country | Israel |
| IPO Date | May 10, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Amir Reichman |
Contact Details
Jerusalem BioPark Building Jerusalem,
JM 9112001 Israel
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| CUSIP Number | 09073Q402 |
| ISIN Number | US09073Q4029 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove SCNI